3 results
To determine whether treatment with RAD001 10 mg/d plus Sandostatin LAR® prolongs the progression free survival (PFS) compared to treatment with Sandostatin LAR® alone in patients with advanced carcinoid tumor.
Primary: To allow continued use of everolimus to patients receiving everolimus in a Novartis-sponsoredstudy which has reached its objectives and who are benefitting from treatment with everolimus as defined in the parent protocolSecondary: To…
Determining the feasibility of SLN detection in the neck of oral cancer patients using a magnetic tracer (Sienna+®), MRI and hand-held magnetometer (SentiMag®).When the magnetic approach of sentinel node detection is found to be feasible, the main…